CIRCULATING CELL-FREE TUMOR DNA MARKET ANALYSIS

Market Challenges And Opportunities

The global Circulating Cell-free Tumor DNA Market's growth can be hindered by disadvantages associated with circulating cell-free tumor DNA analysis like some tests require prior knowledge of tumor mutations, results can be semiquantitative, etc. The use of circulating cell-free tumor DNA tests for the diagnosis of cancer is expected to drive the global Circulating Cell-free Tumor DNA Market over the forecast period. For instance, in January 2022, a report published by Springer Nature Limited, a scientific journal, stated that cell-free tumor DNA analysis represents a promising method for the diagnosis, treatment selection, and clinical follow-up of cancer patients.

Global Circulating Cell-free Tumor DNA Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

The COVID-19 pandemic had a negative impact on the global Circulating Cell-free Tumor DNA Market. For instance, in September 2020, according to an article published by the American Society of Clinical Oncology, a professional organization committed to conquering cancer through research, education, prevention, and delivery of high-quality patient care, stated that a detrimental impact of the COVID-19 pandemic on cancer care was observed during the COVID-19 pandemic.

Global Circulating Cell-free Tumor DNA Market: Restraint

The global Circulating Cell-free Tumor DNA Market can be hindered by disadvantages associated with circulating cell-free tumor DNA. For instance, in January 2022, a report published on MDPI, a publisher of open-access scientific journals, stated the disadvantages of cell-free tumor DNA detection are that some tests require prior knowledge of tumor mutations, results can be semi-quantitative, the source of cfDNA can be from multiple sources (apoptosis, graft rejection, immune cells vs. tumor cells, etc.). ) and analytical methods may involve technical difficulties.